What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast

Mycoses

Volumn 54, Issue 5, 2011, Pages 434-441

  Savini, Vincenzo ^a   Catavitello, Chiara ^a   Onofrillo, Daniela ^a   Masciarelli, Gioviana ^a   Astolfi, Daniela ^a   Balbinot, Andrea ^a   Febbo, Fabio ^a   D'Amario, Claudio ^b   D'Antonio, Domenico ^a  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b San Liberatore Hospital   (Italy)

Author keywords

Antifungal agents; Candidaemia; Fungaemia; Yeast

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POLYENE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; COMORBIDITY; CROSS RESISTANCE; DOSE RESPONSE; FUNGAL GENOME; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TAXONOMY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; MICROBIAL SENSITIVITY TESTS; TREATMENT FAILURE;

FUNGI; PICHIA GUILLIERMONDII;

EID: 79961208456     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01960.x     Document Type: Review

References (69)

1. Chakrabarti A, Mohan B, Shrivastava SK, Marak RS, Ghosh A, Ray P. Change in distribution & antifungal susceptibility of Candida species isolated from candidaemia cases in a tertiary care centre during 1996-2000. Indian J Med Res 2002; 116: 5-12.
2. Chakrabarti A, Chatterjee SS, Rao KL et al. Recent experience with fungaemia: change in species distribution and azole resistance. Scand J Infect Dis 2009; 41: 275-84.
3. Savini V, Catavitello C, Manna A et al. Two cases of vaginitis caused by itraconazole-resistant Saccharomyces cerevisiae and a review of recently published studies. Mycopathologia 2008; 166: 47-50.
4. Savini V, Sozio F, Catavitello C et al. Femoral prosthesis infection by Rhodotorula mucilaginosa. J Clin Microbiol 2008; 46: 3544-5.
5. Savini V, Catavitello C, Balbinot A et al. Multidrug resistant Geotrichum capitatum from a haematology ward. Mycoses 2010. May 17 [Epub ahead of print].
6. Di Bonaventura G, Pompilio A, Picciani C, Iezzi M, D'Antonio D, Piccolomini R. Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance. Antimicrob Agents Chemother 2006; 50: 3269-76.
7. Borg-von Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007; 60: 424-8.
8. Desnos-Ollivier M, Ragon M, Robert V, Raoux D, Gantier JC, Dromer F. Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol 2008; 46: 3237-42.
9. Barchiesi F, Spreghini E, Tomassetti S et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006; 50: 2719-27.
10. Savini V, Catavitello C, Di Marzio I et al. Pan-azole-resistant Candida guilliermondii from a leukemia patient's silent funguria. Mycopathologia 2010; 169: 457-9.
11. Passos XS, Sales WS, Marciel PJ et al. Candida colonization in intensive care unit patients' urine. Mem Inst Oswaldo Cruz 2005; 100: 925-8.
12. Pfaller MA, Diekema DJ, Mendez M et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44: 3551-6.
13. Medeiros EA, Lott TJ, Colombo AL et al. Evidence for a pseudo-outbreak of Candida guilliermondii fungemia in a university hospital in Brazil. J Clin Microbiol 2007; 45: 942-7.
14. Vaughan-Martini A, Kurtzman CP, Meyer SA et al. Two new species in the Pichia guilliermondii clade: Pichia caribbica sp. nov., the ascosporic state of Candida fermentati, and Candida carpophila comb. nov. FEMS Yeast Res 2005; 5: 463-9.
15. Lan L, Xu J. Multiple gene genealogical analyses suggest divergence and recent clonal dispersal in the opportunistic human pathogen Candida guilliermondii. Microbiology 2006; 152(Pt 5): 1539-49.
16. San Millán RM, Wu LC, Salkin IF, Lehmann PF. Clinical isolates of Candida guilliermondii include Candida fermentati. Int J Syst Bacteriol 1997; 47: 385-93.
17. Nishikawa A, Sugita T, Shinoda T. Differentiation between Debaryomyces hansenii/Candida famata complex and Candida guilliermondii by polymerase chain reaction. FEMS Immunol Med Microbiol 1997; 19: 125-9.
18. McManners J, Samaranayake LP. Suppurative oral candidosis. Review of the literature and report of a case. Int J Oral Maxillofac Surg 1990; 19: 257-9.
19. Jewtuchowicz VM, Brusca MI, Mujica MT et al. Subgingival distribution of yeast and their antifungal susceptibility in immunocompetent subjects with and without dental devices. Acta Odontol Latinoam 2007; 20: 17-22.
20. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
21. Krcmery V. Candidemia in cancer patients. Risk factors and outcome in 140 episodes from a single cancer institution. Acta Chemother 1999; 5: 133-45.
22. Girmenia C, Pizzarelli G, Cristini F et al. Candida guilliermondii fungemia in patients with hematologic malignancies. J Clin Microbiol 2006; 44: 2458-64.
23. Kabbara N, Lacroix C, Peffault de Latour R, Socié G, Ghannoum M, Ribaud P. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008; 93: 639-40.
24. Yagupsky P, Dagan R, Chipman M, Goldschmied-Reouven A, Zmora E, Karplus M. Pseudooutbreak of Candida guilliermondii fungemia in a neonatal intensive care unit. Pediatr Infect Dis J 1991; 10: 928-32.
25. Larone DH. Medically Important Fungi - A Guide to Identification, 3rd edn. Washington, D.C.: ASM Press, 1995.
26. Sutton DA, Fothergill AW, Rinaldi MG (ed.). Guide to Clinically Significant Fungi, 1st edn. Baltimore: Williams & Wilkins, 1998.
27. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
28. Colombo AL, Nucci M, Salomão R et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34: 281-6.
29. Dick JD, Rosengard BR, Merz WG, Stuart RK, Hutchins GM, Saral R. Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Ann Intern Med 1985; 102: 67-68.
30. Tietz HJ, Czaika V, Sterry W. Case report. Osteomyelitis caused by high resistant Candida guilliermondii. Mycoses 1999; 42: 577-80.
31. Masala L, Luzzati R, Maccacaro L, Antozzi L, Concia E, Fontana R. Nosocomial cluster of Candida guillermondii fungemia in surgical patients. Eur J Clin Microbiol Infect Dis 2003; 22: 686-8.
32. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115-25.
33. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-8.
34. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
35. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20: 571-5.
36. Lecciones JA, Lee JW, Navarro EE et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 14: 875-83.
37. Walsh TJ, Gonzalez C, Roilides E et al. Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin Infect Dis 1995; 20: 900-6.
38. White M. Epidemiology of invasive candidiasis. Int J Infect Dis 1997; 51: 7-10.
39. Huttova M, Hartmanova I, Kralinsky K et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr Infect Dis J 1998; 17: 1012-5.
40. Kaiserova E, Krcmery V Jr. Fungemia in patients with cancer. Pediatr Infect Dis J 1998; 19: 844-5.
41. Kralovicova K, Spanik S, Oravcova E et al. Fungemia in cancer patients undergoing chemotherapy versus surgery: risk factors, etiology and outcome. Scand J Infect Dis 1997; 29: 301-4.
42. Krcmery V Jr. Risk factors and outcome of non-albicans candidemia: report of 38 cases. Acta Chemother 1998; 8: 23-28.
43. Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int J Antimicrob Agents 2008; 32: 511-4.
44. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109, 496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
45. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150: 101-15.
46. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109, 496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996; 40: 1948-9.
47. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-21.
48. Cuenca-Estrella M, Rodero L, García-Effrón G, Rodriguez-Tudela JL. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother 2002; 49: 981-7.
49. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-54.
50. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-31.
51. Pfaller MA, Diekema DJ, Colombo AL et al. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44: 3578-82.
52. Pfaller MA, Diekema DJ, Rinaldi MG. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43: 5848-59.
53. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN; International Fungal Surveillance Participant Group. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78-83.
54. Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA; FIMUA-ECMM Candidaemia Study Group. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 2003; 52: 679-82.
55. van't Wout JW. Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis 1996; 15: 238-42.
56. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988; 84: 826-32.
57. To WK, Fothergill AW, Rinaldi MG. Comparative evaluation of macrodilution and Alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 1995; 33: 2660-4.
58. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009; 69: 361-92.
59. Savini V, Catavitello C, Bianco A, Balbinot A, D'Antonio F, D'Antonio D. Azole resistant Candida glabrata vulvovaginitis treated with boric acid. Eur J Obstet Gynecol Reprod Biol 2009; 147: 112.
60. Chiu YS, Chang SC, Hsueh PR, Wang JL, Sun HY, Chen YC. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest. J Microbiol Immunol Infect 2006; 39: 335-41.
61. Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance. Fungal Genet Biol 2010; 47: 117-26.
62. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-73.
63. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
64. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-68.
65. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6. Erratum in: J Clin Microbiol 2008; 46: 3184-5.
66. Di Bonaventura G, Spedicato I, Picciani C, D'Antonio D, Piccolomini R. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother 2004; 48: 4453-6.
67. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2, 500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-7.
68. Della Vittoria A, Arzeni D, Manso E, Scalise G. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006; 50: 2719-27.
69. Dannaoui E, Lortholary O, Raoux D et al. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother 2008; 52: 778-81.